BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 11, 2026
Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
Gastrointestinal, BioWorld Science RSS Feed RSS

Liver disease
Gastrointestinal

Novel quinazolinone-based COP1 modulators for NAFLD disclosed

April 12, 2023
Deregulation of enzymes that control lipid turnover such as adipose triglyceride lipase (ATGL) is an essential contributor to nonalcoholic fatty liver disease. Recent studies suggest that a fraction of the cytosolic pool of ATGL is proteasomal degraded by E3 ligase constitutive photomorphogenesis protein 1 (COP1).
Read More
Liver illustration
Biomarkers

Chromosome locus 19p13.3 variant tied to increased ARID3A expression and risk of primary biliary cholangitis

April 4, 2023
Primary biliary cholangitis (PBC) is the most common autoimmune liver disease; several genome-wide association studies have suggested chromosome locus 19p13.3 is associated with PBC pathology. Chinese researchers conducted a case-control study to unveil genetic variants in the 19p13.3 locus associated with PBC. The meta-analysis included 1,931 individuals with PBC and 7,852 controls.
Read More
Gastrointestinal

Eli Lilly discovers new AhR agonists

April 4, 2023
Eli Lilly and Co. has described aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of psoriasis, ulcerative colitis, Crohn’s disease, graft-vs.-host disease and multiple sclerosis.
Read More
3D illustration of heart cross section
Cardiovascular

Proqr Therapeutics announces pipeline programs for cholestatic and cardiovascular diseases

March 30, 2023
Proqr Therapeutics NV has announced initial pipeline programs focused on cholestatic and...
Read More
Gastrointestinal

In vivo study shows that PCK1 deficiency triggers MAFLD through the PI3K/AKT/PDGF axis

March 28, 2023
Metabolic-associated fatty liver disease (MAFLD) is a condition that encompasses a range of liver disorders, from steatosis to fibrosis. In a recent study, researchers investigated the role of phosphoenolpyruvate carboxykinase 1 (PCK1) in MAFLD progression in vivo. This work found that deficiency of the gluconeogenic enzyme PCK1 promoted the development of MAFLD through activation of the PI3K/AKT/PDGF axis.
Read More
Illustration of intestines overlayed on human torso
Gastrointestinal

Rare cell type drives both gut discomfort and anxiety symptoms

March 28, 2023
By Xavier Bofill Bruna
A rare cell type in the gut, the enterochromaffin (EC) cell, drove both gut discomfort and anxiety symptoms in animal models of gastrointestinal pain. Furthermore, the cells reacted differently in male and female mice, opening up new ways to understand and investigate the higher prevalence of gut disorders in women.
Read More
Liver illustration
Gastrointestinal

Discovery of novel CLK1 inhibitors for the treatment of acute liver injury

March 27, 2023
Researchers from Chengdu Zeling Biomedical Technology Co. Ltd. presented the discovery and...
Read More
DNA, drug development concept art.
Drug Design, Drug Delivery & Technologies

Moderna and Generation Bio collaborate to develop nonviral genetic medicines

March 24, 2023
Moderna Inc. and Generation Bio Co. have entered into a strategic collaboration to combine Moderna’s biological and technical expertise...
Read More
Sculpture of Santiago Ramon y Cajal
Gastrointestinal

Condensates allow gut bacteria to adapt to the lean life

March 21, 2023
By Anette Breindl
Gut bacteria used liquid-liquid phase separation (LLPS) to organize themselves into condensates, which allowed them to adapt to nutrient deprivation, enabling them to colonize the gut. In experiments reported in the March 17, 2023, issue of Science, investigators showed that a mutant of the beneficial gut bacterium Bacteroides thetaiotaomicron was “highly defective in competitiveness, in its ability to colonize the mammalian gut,” senior author Eduardo Groisman told BioWorld. “Our paper provides the first example in which [LLPS] matters in bacterial host interactions.”
Read More
Liver disease
Gastrointestinal

Silencing Timm13 reduces the expression of profibrogenic and apoptosis-related gene in mouse hepatocytes

March 17, 2023
Researchers from the First Affiliated Hospital of Guangxi Medical University presented data from a study that aimed to assess the association between translocase of the inner mitochondrial membrane 13 (Timm13) and liver fibrosis.
Read More
Previous 1 2 … 40 41 42 43 44 45 46 47 48 … 676 677 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 9, 2026
  • 3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

    Skape Bio unlocks GPCR targets with de novo-designed miniproteins

    BioWorld
    Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
  • Wuxi Apptec signage

    Wuxi Apptec insists it’s ‘not a Chinese military company’

    BioWorld
    Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
  • Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

    BioWorld Science
    Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing